TeneoBio, Inc.

9 articles with TeneoBio, Inc.

• Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

  10/17/2019

  Selexis SA and Teneobio, Inc. announced that they have signed three commercial license agreements for the development of Teneobio’s Human Heavy-Chain Antibodies, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer.

• AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

  2/11/2019

  AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

• 

  AbbVie Partners With Teneobio, Secures Spot in BCMA Race to Treat Multiple Myeloma

  2/11/2019

  AbbVie is taking a $90 million plunge into B-cell maturation antigen (BCMA)-targeting immunotherapeutics against multiple myeloma in a collaborative deal with Menlo Park, Calif.-based Teneobio, Inc.

• Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies

  1/8/2018

  TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.

• TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology

  12/11/2017

  Data showed results from the application of TeneoBio’s suite of technologies in the generation of the lead therapeutic candidate.

• Selexis SA And TeneoBio, Inc.Team Up To Advance The Development Of Uniabs Targeting Cancer

  6/12/2017

• TeneoBio, Inc. And Poseida Therapeutics Announce License Agreement For The Use Of Unidab In CAR T-Cell Therapy

  5/22/2017

• TeneoBio, Inc.’s Next Generation T Cell Redirection Antibody Platform For Cancer Biotherapeutics Offers Prospects Of Reducing Cytokine Release

  5/1/2017

• TeneoBio, Inc.’s Next Generation T Cell Redirection Antibody Platform For Cancer Biotherapeutics

  5/1/2017